Introduction: As per the International Diabetes Federation, 422 million people are living with diabetes across the world, and it is expected to rise to a whooping figure of 592 million in 2035, of which 79.4 million diabetics will be from India. Worsening of glycemic control deteriorates lipid & lipoprotein abnormalities in Diabetes Mellitus. Glycated hemoglobin (HbA1c) is a gold–standard measure of long–term glycemic control. Objective: to study the pattern of dyslipidemia and to determine the correlation of Glycated hemoglobin (HbA1C) with dyslipidemia in newly diagnosed type 2 diabetes mellitus patients. Material and method: A cross–sectional study was carried out among 200 newly diagnosed type 2 Diabetes Mellitus patients from Feb 2019 to July 2019 in the Department of Medicine of a tertiary care teaching hospital in south–eastern Rajasthan. Venous blood samples were collected from all the subjects after at least 8 hours fasting. The Serum was later used for analyzing Fasting Blood Glucose (FBG), Lipid Profile and HbA1c. Results: 70 (76.09%) females and 84 (77.8%) males were found to have dyslipidemia. Patients with HbA1c values greater than 7.0% had significantly higher values of FBG, TG, LDL, VLDL and risk ratio TC/ HDL, LDL/HDL. There was a significant positive correlation between HbA1c with TG, LDL and VLDL. Conclusion: The study revealed a significant correlation between HbA1c and various circulating lipid parameters. This implies that HbA1c can be used as a potential biomarker for predicting dyslipidemia in patients with T2DM.